Elevance Health Inc.

(New York Stock Exchange)
Back to all articles
Bullish +55

ARGA Investment Management LP Has $60.03 Million Position in Elevance ...

AI-generated analysis

πŸ“‰ ARGA Investment Management LP reduced its Elevance Health holdings by 26.2%, selling 72,692 shares to retain a $60 million position.

πŸ“ˆ Norges Bank established a new $1.06 billion position in Elevance Health during the fourth quarter.

πŸ“ˆ Wellington Management Group increased its stake by 25.2% to own 8.29 million shares valued at $2.91 billion.

πŸ“ˆ Price T Rowe Associates Inc. MD grew its holdings by 27.5%, now owning 7.45 million shares worth $2.61 billion.

πŸ“ˆ Invesco Ltd. significantly expanded its position by 50.3% to hold 3.9 million shares valued at $1.37 billion.

πŸ“ˆ Bank of New York Mellon Corp raised its stake by 79.3%, purchasing an additional 1.07 million shares.

🏦 Institutional ownership of Elevance Health stands at 89.24% as of the latest filings.

πŸ’° The company recently paid a quarterly dividend of $1.72 per share, resulting in a 1.7% annualized yield.

πŸ“Š Barclays raised its price target to $480 and maintained an 'overweight' rating on the stock.

πŸ“ˆ JPMorgan Chase increased its price objective to $476 with an 'overweight' recommendation.

πŸš€ Wall Street Zen upgraded Elevance Health from a 'hold' to a 'buy' rating in late June.

πŸ“‰ Jefferies Financial Group lowered its price target to $391 but maintained a 'buy' rating.

πŸ‘” CEO Gail Boudreaux leads the company's strategic focus on integrated health care and benefit delivery.

🏒 Elevance Health operates as a large U.S.-based health benefits provider headquartered in Indianapolis.

πŸ“‰ The stock trades at a PE ratio of 17.72 with a market capitalization of $90.46 billion.

πŸ“‰ Director Robert L. Dixon, Jr. sold 151 shares for approximately $60,667 in a recent transaction.

Bullish Signals
  • Major institutional investors including Norges Bank, Wellington Management Group, and Price T Rowe Associates significantly increased their stakes in the fourth quarter.
  • Barclays raised its price target to $480 and assigned an 'overweight' rating, indicating strong confidence in future performance.
  • JPMorgan Chase increased its price target to $476 with an 'overweight' rating, reinforcing bullish analyst sentiment.
  • Wall Street Zen upgraded the stock from a 'hold' to a 'buy' rating, signaling improved investment outlook.
  • The company maintains a healthy dividend yield of 1.7% with a payout ratio of 29.26%, providing income to shareholders.
  • Invesco Ltd. more than doubled its holdings by 50.3%, demonstrating strong institutional interest in the stock.
Risk Factors
  • ARGA Investment Management LP reduced its position by 26.2% in the first quarter, indicating a decrease in confidence from this specific fund.
  • Jefferies Financial Group lowered its price target to $391, suggesting some analysts see limited upside at current levels.
  • The stock has experienced volatility with a 52-week low of $273.71 compared to a high of $427.64.
Full Analysis
ARGA Investment Management LP reduced its stake in Elevance Health, Inc. (NYSE:ELV) by 26.2% in the first quarter, selling 72,692 shares to hold a remaining position of 205,063 shares valued at approximately $60 million. This reduction brings the stock to its 11th largest position within the fund's portfolio, representing about 2.0% of total holdings. Conversely, several major institutional investors significantly increased their exposure to Elevance Health during the fourth quarter. Norges Bank initiated a new position worth roughly $1.06 billion, while Wellington Management Group grew its stake by 25.2% to a value of $2.91 billion. Other notable increases include Price T Rowe Associates (up 27.5%), Invesco Ltd. (up 50.3%), and Bank of New York Mellon Corp (up 79.3%). Analyst sentiment remains mixed but generally positive, with a consensus rating of 'Moderate Buy' and an average price target of $425.95. Major banks like Barclays and JPMorgan Chase raised their price targets to $480 and $476 respectively, citing overweight ratings, while Wall Street Zen upgraded the stock to a buy rating. The company maintains a market cap of $90.46 billion with a dividend yield of 1.7%.